Faculty & Staff at TUC
Michael B. Clearfield
College: COM
Department: Deans Office
Title: Dean
Phone: (707) 638-5982
Fax: (707) 638-5924
E-Mail: mclearfi@touro.edu
Office: Administration & Faculty 1, Rm. 220
| Institution | Degree | Field of Study | Obtained |
| American Osteopathic Board of Internal Medicine | Board Certified | Internal Medicine | 1981 |
| Chicago College of Osteopathic Medicine | Doctor of Osteopathy | Doctor of Osteopathy | 1975 |
| Albright College | Bachelor of Science | 1971 |
TCOM/University of North Texas Health Science Center (Director/Co-Director)
2002 - present Associate Dean for Clinical Research
1984-86 Director, Internal Medicine Residency Program, Texas College of Osteopathic
Medicine
1982-86 Course Director, Internal Medicine Clinical Clerkship
1982-84 Director, Internal Medicine Residency Program, Fort Worth Osteopathic Medical
Center
1982-84 Course Director, Internal Medicine Course
1981 Course Co-Director Problem Solving Course
1980 Course Co-Director Medicine/Surgery Course
Phase II Double Blinded Randomized Controlled Parallel Group Study evaluating the
Efficacy and Safety of three doses of RO4607381 Combined with Pravastatin over a 12
week period in Patients with Low HDL-C
Principal Investigator
2005-06 Funded $90,331 Hoffman-LaRoche
Research, Education and Metabolic Studies (DREAMS)
Traditional and Emerging Risk Factors for Individuals Developing Diabetes, Metabolic
Syndrome and Coronary Heart Disease. Project 2.
Principal Investigator
2004-2005 Funded $401,419 Centers for Disease Control and Prevention
2005-2006 Funded $365,435 Centers for Disease Control and Prevention
A 6 week Open label Randomized Multi-Center Phase IIIb Study to Compare Efficacy and
Safety of Rosuvastatin 10 mg with Atorvastatin 20 mg in Subjects with Hypercholesterolemia
and either a History of CHD or CHD Risk Equivalent (PULSAR)
Principal Investigator
2003-2004 Funded $28,000 Astra-Zeneca
A Randomized, Double Blind, Placebo –Controlled , Multicenter Phase III Study of Rosuvastatin
20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels
of LDL-C and Elevated Levels of C-Reactive Protein. (JUPITER)
Principal Investigator.
2003-2006 Funded by Astra-Zeneca, $96,000
Hypo-Responders to Statins, UNTHSC Intramural Grant,
2000, Martin Weiss, D.O. Principal Investigator; $10,400.
A 24 week Randomized Double-blind Multicenter Trial to Evaluate the Efficacy and Safety
of Starting and Maximum Doses of ZD4522 and Atorvostatin in the Treatment of Subjects
with Hypercholesterolemia and documented Atherosclerosis
Principal Investigator;
1999 Funded by Astra-Zeneca, $46,600.
A Multi-Center, Randomized, Parallel Group 8 Week Comparative Dose Efficacy and Safety
of Once Daily Atorvastatin with Other Statins. (CURVES).
Principal Investigator.
1996, Funded by Parke-Davis $42,000.
Atherosclerotic Risk Reduction and Atorvastatin.
1996 Funded by Parke-Davis. Principal Investigator, $42,000.
Texas Coronary Atherosclerosis Prevention Study. A Randomized Double-Blind, Placebo
Controlled Trial of the Effect of Lovastatin on the Incidence of Primary Coronary
Heart Disease in Patients with Mild to Moderate Elevations in Total and LDL Cholesterol
in Combination with Low-HDL Cholesterol.
1992-1997, Funded by Merck Sharp and Dohme.
Principal Investigator, $6,400,000
Effect of Pravastatin on Continuing Hypercholesterolemia.
1991-1992 Funded by Bristol Meyer-Squibb. Co-Investigator. $12,000.
Educational Grant for Lipid Symposium.
1990, Funded by Merck, Sharp & Dohme, $5,000.
The Potential Protective Effect of Captopril Against the Deposition of Low Density
Lipoprotein (LDL) Cholesterol in the Arteries",
1990 Funded by E.R. Squibb & Sons, Inc.,
Principal Investigator. $5,000
Educational Grant for Lipid Symposium.
1989, Funded by Merck, Sharp & Dohme, $5,000.
"Regulation of High Density Lipoprotein (HDL) Levels in Human Plasma. Stephen E. Weis,
D.O., Principal Investigator, Michael B. Clearfield, D.O., Co-Investigator, 10% FTE
1989, AOA Research Grant #89-11-299, $14,000
"A Double-Blind Comparative Study of Prinomide vs. Naproxen vs. Placebo in Patients
with Rheumatoid Arthritis",
1988 Funded by Ciba-Geigy Corporation, Bernard R. Rubin, D.O., Principal Investigator,
Michael Clearfield DO co-investigator, $27,990
"An Open-Label Study of Voltaren Treatment in Patients with Rheumatoid Arthritis Using
Arthritis Impact Measurement Scales Protocol MCS #125A",
1987-88 Funded by Ciba-Geigy Corporation, Bernard R. Rubin, D.O., Principal Investigator,
Michael B. Clearfield, D.O. co-investigator $6,000
Boekholdt SM, Arsenault BJ, Mora S, Pedersen TR, LaRosa JC, Nestel PJ, Simes RJ, Durrington P, Hitman GA, Welch KM, DeMicco DA, Zwinderman AH, Clearfield M, Downs JR, Tonkin AM, Colhoun HM, Gotto AM, Ridker PM, Kastelein JJ. On statin LDL-cholesterol, non-HDL –Cholesterol and apolipoprotein B and risk of cardiovascular events; a pooled analysis. J Am Med Assoc (JAMA) 2012;307:1302-1309.
Lack of effect of lowering LDL Cholesterol on Cancer: Meta-analysis of Individual Data from 175,000 peopled in 27 Randomized Trials of Statin Therapy. Cholesterol Treatment Trialists’ (CTT) Collaboration PLoS ONE 2012;7(1):e29849. Epub 2012;Jan 19 http://ww.plosone.org/article/info%2F10.1371%2Fjournal.pone.0029849
Clearfeld MB. Cardiovascular benefits of aggressive cholesterol lowering therapy. J Am Osteo Assoc 2011;111(suppl 3):1-3.
Clearfield M. Combination lipid therapy in type 2 diabetes. Curr Athero Reports 2011;Feb;13(1):1-3.
Clearfield M. Statins in combination: From ARBITER-6 HALTS to ACCORD-What works? Curr Athero Reports 2011;Feb;13L1):4-8.
Efficacy and safety of more intensive lowering of LDL-C: a meta-analysis of data from 170,000 participants in 26 randomized trials. Cholesterol Treatment Trialist’ (CTT) Collaboration. Lancet 2010;376:1670-1681.
Clearfield MB. Altering the pathophysiology of atherosclerosis: The multidimensional role of statins. J Am Osteo Assoc 2010;110(suppl 4):52-56.
Hiserote P, Clearfield M. Treating risk components of the metabolic syndrome. J Am Osteo Assoc 2010;109(suppl 3):e56-eS13
Sattar N, Preiss D, Murray H, Welsh P, Buckley B, deCraen A, Seshasai S, McMurray J, Freeman D, Jukema J, Macfarlane P, Packard C, Stott D, Westendrop R, Shepherd J, Davis B, Pressel S, Marchioli R, Marfisi R, Maggioni A, Tavazzi L, Tognoni G, Kjekshus J, Pedersen T, Cook T, Gotto A, Clearfield M, Downs J, Nakamura H, Ohashi Y, Misuno K, Ray K, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010;375:735-742
Clearfield M. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Curr Atheroscl Rep 2010;Jan;12(1):8-10.
Clearfield M. Rosuvastatin and clinical outcomes in individuals who are not deemed appropriate for baseline statin therapy. Curr Atheroscler Rep 2010:Jan;12(1):5-7.
Clearfield M. New evidence extending the benefit of treating LDL-C beyond the current guidelines. Curr Atheroscl Rep 2010:Jan;12(1):1-4.
Bray GA, Clearfield MB, Fintel DJ, Nelinson DS. Overweight and Obesity: the pathogenesis of cardiometabolic risk. Clin Cornerstone 2009;9(4):30-40.
Cui Y, Watson D, Girman C, Shapiro D, Gotto AM, Hiserote P, Clearfield M. Effects of increasing High Density Lipoprotein Cholesterol and decreasing Low Density Lipoprotein Cholesterol on the Incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol 2009;104:829-834.
Licciardone JC, Clearfield MB, Guillory VJ. Clinical Practice Characteristics of Osteopathic and Allopathic Primary Care Physicians at Academic Health Centers: Results from the National Ambulatory Medical Care Survey. Academic Medicine 2009;84:744-750.
Shah BM, Kemp R, Clearfield M. Using statins to treat ‘healthy’ patients: are we there yet? Expert Review of Pharmacoeconomics and Outcomes Research. 2009;9(2):103-105.
Hiserote PA, Clearfield M. Predicting Cardiometabolic Risk: The Evolution Continues Whole Patient Supplement to JAOA/DO 2009;7(1):7-9
Clearfield M Clinical Trials Reports (ENHANCE,CORONA,CTT-Diabetes) Curr Atheroscl Reports 2009;11(1):3-8
Clearfield M. Another Inconvenient Truth: Combining the Risks from Obesity and Metabolic Syndrome with Global Warming. Curr Atheroscl Reports, 2008;10:273-276.
Consensus Report of the American Osteopathic Association, American College of Osteopathic Internists, American College of Osteopathic Family Physicians, American Academy of Physician Assistants and the Diabetes Consortium. Addressing Overweight and Obesity: Evolving to a Medical Consensus. J Am Osteopath Assoc 2008;Suppl 1:108:S2-S15.
Clearfield M. Clinical Trials Reports (SAGE, METEOR, ILLUSTRATE) Curr Atheroscl Reports, 2008;10(1):5-10.
Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomized trials of statins:a meta-analysis. Cholesterol Treatment Trialists (CTT) Collaborators Lancet 2008;371:117-125
Clearfield M, Smith-Barbaro P, Guillory VJ, Cavalieri TA, Wood DL, Sharp GF,HahnMB. Research Funding at Colleges of Osteopathic Medicine: 15 Years of Growth. J Am Osteopath Assoc 2007;107:469-478.
Clearfield M, Smith-Barbaro P, Guillory VJ, Cavalieri TA, , Hahn MB. How can we keep research growing at Colleges of Osteopathic Medicine? J Am Osteopath Assoc 2007;107:463-465.
Clearfield M. Clinical Trials Report (IDEAL, ASTEROID, Cholesterol Treatment Trialists Collaboration-CTT) Curr Atheroscl Reports 2007;9(1):5-9.
Clearfield MB, Amerena J, Bassand JP, Hernandez-Garcia HR, Miller SS, Sosef FM, Palmer
MK, Bryzinski BS. Comparison of the efficacy and safety of rosuvastatin 10 mg and
atorvastatin 20 mg in high risk patients with hypercholesterolemia-Prospective study
to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
Trials 2006;7:35 doi:1186/1745-6215-7-35
Clearfield M. Statins and the Primary Prevention of Cardiovascular Disease. Current
Atherosclerosis Reports. 2006;8:390-396
Alexander J, Clearfield M. Cardiovascular disease after menopause: a growing epidemic.
Minerva Ginecologica 2006;58:35-40.
Clearfield M. Clinical Trials Report
Current Atherosclerosis Reports 2006;8:7-12.
Clearfield M, Downs JR, Lee M, Langendorfer A, McConathy W, Gotto AM. Implications
from the Air Force/Texas Atherosclerosis Prevention Study for the Adult Treatment
Panel III Guidelines American Journal of Cardiology 2005;96:1674-1680
Yurvati AO, Carnes M, Clearfield M, Stoll S, McConathy WJ. Hemodynamic effects of
Osteopathic Manipulative Treatment immediately after coronary bypass surgery. Journal
of the American Osteopathic Association 2005;105:475-481
Clearfield M. C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease.
Journal of the American Osteopathic Association 2005;105:409-416.
Cholesterol Treatment Trialists (CTT) Efficacy and safety of cholesterol lowering
treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized
trial of statins. Lancet 2005;366:1267-1278.
Clearfield M. Clinical Trials Report
Current Atherosclerosis Reports 2005;7(1):7-10.
Clearfield MB. The Future looks promising for the Treatment of Patients with Coronary
Heart Disease. Journal of the American Osteopathic Association 2004;9:51-52
Clearfield M. Coronary Heart Disease Risk Reduction in Postmenopausal Women: The Role
of Statin Therapy and Hormone Replacement Therapy
Preventive Cardiology 2004;7:131-136
Girman CJ, Rhodes T, Mercuri M, Pyorala K, Pederson TR, Beere PA, Gotto AM, Clearfield
M. The Metabolic Syndrome and Risk of Major Coronary Events in the Scandinavian Simvastatin
Survival Study and the Air Force/Texas Coronary Atherosclerosis Prevention Study.
American Journal of Cardiology 2004;93:136-141.
Clearfield M. Future Directions in Dyslipidemia Management. John’s Hopkins University
Advanced Studies in Medicine. 2004;4(1B):S53-S60.
Clearfield M. Evolution of cholesterol management therapies: Exploiting potential
for further improvement. American Journal of Therapeutics 2003;Jul-Aug;10(4):275-281.
Clearfield MB. A novel therapeutic approach to dyslipidemia.
Journal American Osteopathic Association 2003;103(1):S16-S20.
Clearfield MB. The National Cholesterol Education Program Adult Treatment Panel III
Guidelines. Journal American Osteopathic Association 2003;103(1):S1-4.
Clearfield MB. Under-identification and under-treatment of dyslipidemia. Journal American
Osteopathic Association 2003;103(1):S5-8.
Clearfield MB, Weis SE, Willis JM, Vasenius KA, McConathy WJ. Lablility of serum low-density
lipoprotein cholesterol during screening of Air Force/Texas Coronary Atherosclerosis
Prevention Study (ACAPS/TexCAPS) cohort. Journal American Osteopathic Association
2002;102(7):377-384.
Ridker PM, Shih J, Cook TJ, Clearfield MB, Downs JR, Pradhan AD, Weis SE, Gotto AM.
Plasma Homocysteine Concentration, Statin Therapy, and the Risk of First Acute Coronary
Events. Circulation 2002;105:1776-1179.
Clearfield M Adult Treatment Panel III: Do we need another set of Cholesterol Guidelines.
Journal American Osteopathic Association 2002;102(5):S6-11.
Clearfield M. Statins: Balancing benefits, efficacy and safety.
Expert Opinion on Pharmacology. 2002;3(5):469-477.
Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro D, Stein E, Langendorfer
A. Beere PA, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention Study:
Efficacy and Tolerability of Long-Term Treatment with Lovastatin in Women.
Journal of Women’s Health & Gender Based Medicine. 2001;10(10):1-11.
.Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles SJ, Gotto AM. Measurement
of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention
of Acute Coronary Events. New England Journal of Medicine. 2001;344(26):1959-1965.
Clearfield M. New Guidelines for the new millennium.
Journal American Osteopathic Association 2001;101(6):355,363.
Downs JR, Clearfield M, Tyroler A, Whitney EJ, Kruyer W, Langendorfer A, Zagrebelsky,
Shapiro D, Beere PA, Gotto Am. Air Force/Texas Coroanry Atherosclerosis Prevention
Study
(AFCAPS/TexCAPS): Additional Perspectives on Tolerability of Long-Term Treatment with
Lovastatin. American Journal of Cardiology 2001:87:1074-1079.
Gotto AM, Whitney E, Stein E, Shapiro DR, Clearfield M, Weis S, Jou J, Langendorfer
A, Beere P, Watson D, Downs JR, de Cani J. Relation Between Baseline and On-Treatment
Lipid parameters and First Acute Major Coronary Event in the Air Force/Texas Coronary
Atherosclerosis Prevention Study. Circulation. 2000;101:477-484.
Osborn GG, Meoli FG, Buser BR, Clearfield MB, Bruno JP, Sumner-Truax L. The Comprehensive
Osteopathic Medical Licensing Examination, COMLEX-USA:A new paradigm in testing and
evaluation. Journal American Osteopathic Association. 2000;100:105-111.
Clearfield M, Whitney EJ, Weis S, Downs JR, Shapiro DR, Stein EA, Watson DJ, Langendorfer
A, Beere PA, Stamler J, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention
Study (AFCAPS/TexCAPS): Baseline characteristics and comparison with USA population.
Journal of Cardiovascular Risk 2000;7:125-133.
Shores JH, Clearfield M, Alexander J. An Index of Students Satisfaction with Instruction.
Academic Medicine. 2000;75(10):S106-108.
Gotto Am, Boccuzzi SJ, Cook JR, Alexander CM, Roehm JB, Meyer GS, Clearfield MB, Weis
S, Whitney E. Effect of Lovastatin on Cardiovascular Resource Utilization and Costs
in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
American Journal of Cardiology 2000;86:1176-1181.
Mathe AJ, Clearfield MB. Long-term therapy of coronary artery disease: a vascular
biology perspective. Journal American Osteopathic Association 2000;100(11):S13-16.
Jones P, Kafoneh S, Laurera I, Hunninghake D, Curves Investigators. Comparative dose
efficacy study of Atorvastatin versus Simvastatin, Pravastatin, Lovastatin and Fluvastatin
in patients with hypercholesterolemia (Curves Study).
American Journal of Cardiology. 1998;81(5):582-587.
Lacko AG, Kudchodkar BJ, Loney WW, Clearfield MB, Weis S. Decrease in high density
lipoprotein cholesterol (HDL-C) levels following Gemfibrozil therapy.
Clinical Chemistry Laboratory Medicine 1998;36(6):389-92.
Downs JR, Clearfield MB, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A,
Stein EA, Kruyer MD, Gotto AM. Primary prevention of acute coronary events with Lovastatin
in men and women with average cholesterol levels results of AFCAPS/TexCAPS.
Journal American Medical Association. 1998;279:1615-1622.
Loney WW, Kudchodkar BJ, Weis SE, Clearfield MB, Shores J, Lacko AG. Evaluation of
gemfibrozil therapy: predictive response from lipoprotein subfraction analysis. American
Journal of Therapeutics.1997; 4:301-9.
Shen L, Cavaleri T, Clearfield M, Smoley J. Comparing medical knowledge of osteopathic
medical trainees in DO and MD programs: a random effect meta-analysis.
Journal of the American Osteopathic Association. 1997;97(6):359-362.
Downs JR, Beere PA, Whitney E, Clearfield M, Weis S, Rochen J, Stein EA, Shapiro D,
Langendörfer A, Gotto AM. Design and rationale of the Air Force/Texas coronary atherosclerosis
prevention study (AFCAPS/TEXCAPS).
American Journal of Cardiology. 1997;80:287-93..
Cholesterol Treatment Trialists (CTT) Collaboration. Protocol for a prospective collaborative
overview of all current and planned randomized trials of cholesterol treatment regimens.
Amercian Journal Cardiology. 1995;75:1130-1134.
Knebl J, DeFazio P, Clearfield MB, Little L, McConathy WJ, McPherson R, Lacko AG.
Plasma lipids and cholesterol esterification in Alzheimer's disease. Mechanisms of
Aging and Dev. 1994;73:69-77.
Clearfield MB, Lee N, Armstrong L, DeFazio P, Kudchodkar BJ, Lacko AG. The effect
of Captopril on the oxidation of low density lipoproteins (LDL) in vitro. Pharmacology
and Toxicology. 1994;75:218-221.
Clearfield MB, Wood HS, Vasenius KA. Risk factors other than hypertension and dyslipidemia
to be considered in preventive cardiology.
Journal of Osteopathic Medicine. 1993;14-31.
Clearfield MB. Current management approaches to hyperlipidemia.
Journal of the American Osteopathic Association. 1993(11suppl):1207-1211.
Clearfield MB. Therapeutic implications for dyslipidemia.
Journal of Osteopathic Medicine. 1992;(August):46-50.
Weis S, Clearfield MB, Kudchodkar B, Lacko A. The efficacy of Gemfibrozil therapy
for raising high density lipoprotein levels in hypertriglyceridemic patients. Artery
1992;19(6):353-367.
Lacko AG, Clearfield MB, Weis SE. The role of high density lipoproteins in determining
coronary risk. Tarrant County Physician. March, 1992.
Kudchodkar BJ, Weis SE, Clearfield MB, Lacko AG. Factors influencing plasma high density
cholesterol (HDL-C) levels upon treatment (Rx) with gemfibrozil. Arteriosclerosis
1991;(suppl).November.
Clearfield MB. The role of dyslipidemia in preventive cardiology.
Osteopathic Medical News, 1991;8(7):August.
Clearfield MB. The role of hypertension in preventive cardiology. Part 2.
Osteopathic Medical News, 1990;7(8):August.
Clearfield MB. The role of hypertension in preventive cardiology. Part 1.
Osteopathic Medical News, 1990;7(7):July.
Clearfield MB, Fedorko S, McKinney ME. Physician awareness of elevated cholesterol.
Journal of the American Osteopathic Association, 1990; 90:February.
Clearfield MB. Meperidine hydrochloride induced hypereosinophilia,
Journal of the American Osteopathic Association, 1987;87, September.
Clearfield MB, Trinkle PL. Hypokalemic subclinical neuromyopathy,
Journal of the American Osteopathic Association, 1986;86, December.
Trinkle PL, Clearfield MB. Primary hyperaldosteronism,
Journal of the American Osteopathic Association, 1983;83, November.
Duberstein DL, Efrusy ME, Clearfield MB, Lombardo PR. Primary sclerosing cholangitis
and cholangiocarcinoma: report of two cases,
Journal of the American Osteopathic Association, Vol. 1978;77:March.
Publications – Abstracts, Editorials, Book Chapters
Chapters/Reviews/Books
Weis S, Clearfield M, Downs J, Gotto A. The Air Force/Texas Coronary Atherosclerosis
Prevention Study: Primary Prevention of Acute Major Coronary Events in Women and Men
with Average Cholesterol. Cholesterol-Lowering Therapy-Evaluation of Clinical Trial
Evidence. Edited by Scott Grundy. Marcel Dekker Inc. 151-172, 2000.
Book Review: Clearfield MB. Review of General Internal Medicine: A Self-Assessment
Manual, Journal of the American Osteopathic Association, 1983.
Abstracts
Cui Y, Clearfield M. Non-High Density Lipoprotein Cholesterol is better than LDL-C
in Explaining the Reduction in First Acute Major Coronary Events with Statin Therapy:
A Secondary Analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study
ACC Epidemiology and Prevention 2007 Abstract Number 560
Clearfield M, Kallend D, Palmer M, Sosef F for the PULSAR study investigators. Efficacy
and Safety of Rosuvastatin 10 mg versus Atorvastatin 20 mg: Results of the PULSAR
study. Atherosclerosis 2005;6:104(W16-P-014).
Yurvati A, Carnes M, Clearfield M, Stoll S, McConathy W. Hemodynamic Effects of Osteopathic
Manipulative Treatment Immediately Following Coronary Artery Bypass Surgery. JAOA
2003;103(8):381 P11
Clearfield M, Gotto AM, Downs JR, Nag SS, Jiandong L, Alexander CM, Cook TJ, Beere
PA, Langendorfer A. Impact of Insulin Resistance on Acute Major Coronary Events in
the Air Force/Texas Coronary Atherosclerosis Prevention Study.
Diabetes;2002:Vol 51, suppl 2:pg 1A-738 # 627P.
Clearfield M. Overview of the Safety of Statin Treatment: An Update on Rosuvastatin.
American Society of Hospital Pharmacists. Atlanta Ga. 12/02
Gotto AM, Downs JR, Clearfield M, Weis S, Kruyer W, Whitney E, Stein EA. Follow-up
of the Air Force/Texas Coronary Atherosclerosis Prevention Study Cohort:Persistent
Benefit with Lovastatin Treatment. American Heart Association 74th Scientific Session,
Anaheim Cal 11/01
Ridker PM, Rifai N, Miles JS, Downs JR, Clearfield M, Gotto Am, Cook TJ, Weis S, Langendorfer
A, Beere PA. Relation Between Baseline Homocysteine Levels and Risk of Acute Major
Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study.
American Heart Association 74th Scientific Session, Anaheim Cal 11/01
Clearfield MB, Weis SE, Weiss M, McConathy WM. Hyporesponse to Lovastatin in the Texas
Coronary Atherosclerosis Prevention Study (TexCAPS) Cohort.
UNTHSC Research Appreciation Day 3/01
Shores JH, Clearfield M, Alexander J. An Index of Students Satisfaction with Instruction.
American Association of Medical Colleges, Research in Medical Education Conference.
Chicago Ill. 11/00.
Ridker PM, Rifai, Miles JS, Downs JR, Clearfield M, Gotto AM, Cookd TJ, Langendorfer
A, Beere PA. Lovastatin 20-40 mg/day Lowers High Sensitivity C-Reactive Protein Levels
in AFCAPS/TexCAPS.
American Heart Association 73rd Scientific Session, New Orleans, La. 11/00.
Ridker PM, Rifai N, Downs JR, Clearfield M, Gotto AM, Cook TJ, Langendorfer A. Beere
PA. Relation between baseline C-reactive protein levels and risk of acute major coronary
events in the Air Force/Texas Coronary Atherosclerosis Prevention Study. XXII Congress
of the European Society of Cardiology. Netherlands. European Heart Journal. 21:496,
#2728, 8/00.
Gotto AM. Beere PA, Allen SE, Cook JR, Downs JR, Clearfield M, Weis S Langenorfer
A. Air Force/Texas Atherosclerosis Prevention Study (AFCAPS/TexCAPS)- Benefits of
Lovastatin Treatment in Risk Subgroups Defined by Framingham Risk Equations. American
College of Cardiology 49th Scientific Session. Anaheim California, J American Coll
Cardio 35:313A, 2000.
Kruyer WB, Zagrebelsky V, Whitney EJ, Qinfen Y, Langerdorfer A Beere PA, Shapiiro
Farmer J, Downs JR, Clearfield M, Weis, Gotto AM. Air Force/Texas Atherosclerosis
Prevention Study (AFCAPS/TexCAPS) –The Effect of Treatment with Lovastatin on the
Utilization of Invasive Cardiac Procedures and the Extent of Angiographic Disease.
American College of Cardiology 49th Scientific Session. Anaheim California, J Americ
Coll Cardio 35:325A, 2000.
Gotto AM, Stein EA, Downs JR, Clearfield MB, Weis S, Whitney EJ, Beere PA, Shapiro
DR. Air Force/Texas Coronary Athreosclerosis Prevention Study (AFCAPS/TexCAPS):Relation
of Risk to Baseline Non-HDL Cholesterol. American Heart Association 72nd Scientific
Session. Atlanta, Ga. Circulation Supp I,100(18), I-197, #1017, 1999.
Gotto AM, Whiteny EJ, Stein EA, Shapiro DR, Clearfield MB, Weis SA, Beere PA, Watson
DJ, Downs JR, de Cani JS. Air Force/Texas Coronary Atherosclerosis Prevention Study:
Relative Benefitof Primary Prevention in Subgroups with Different Absolute Risk According
to US NCEP ATP II and Joint European Guidelines. XXI Congress of the European Society
of Cardiology. Barcelona, Spain. European Heart J, 20:473 (Supp #2495) Aug-Sept 1999.
Kruyer WB, Zagrebelsky V, Farmer J, Yu Q, Downs JR, Clearfield MB, Weis S, Whiteny
E, Shapiro DR, Beere PA, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention
Study: Invasive Procedures and Extent of Disease. XXI Congress of the European Society
of Cardiology. Barcelona, Spain. European Heart J, 20;238(Supp #1304) Aug-Sept 1999.
Stein E, Weis S, Downs JR, Clearfield M, Whitney E, Beere P, Gotto AM. Air Force/Texas
Coronary Atherosclerosis Prevention Study:Risk reduction by LDL-C and HDL-C tertiles.
European Atherosclerosis Society. 5/99.
Downs JR, Beere PA, Clearfield MB, Weis S, Whitney EJ, Shapiro DR, Kruyer WB, Watson
DJ, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention Study: Lipid Modification
and Risk Associated with Non-Lipid Risk Factors. American College of Cardiology. New
Orleans, J Amer Coll Cardio, 33:244A, 1999.
Gotto AM, Whitney EJ, Stein EA, Shapiro DR, Clearfield MB, Weis S, Watson DJ, Cook
JR, Beere PA, Downs JR. Predicting Risk of First Acute Major Coronary Events (AMCEs)
in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
American College of Cardiology. New Orleans, J Amer Coll Cardio, 33:263A, 1999.
Clearfield MB, Stein EA, Downs JR, Weis S, Whitney EJ, Shapiro DR, Beere PA, Gotto
AM. Air Force/Texas Coronary Atherosclerosis Prevention Study: Risk Reduction by NCEP
LDL-C Cutpoints. American Heart Association 71st Scientific Session. Circulation 1998
Oct 27;98(17 suppl):I-46.
Downs JR, Clearfield MB, Weis S, Whitney EJ, Shapiro DR, Beere PA, Gotto AM. Air Force/Texas
Coronary Atherosclerosis Prevention Study: Primary Prevention of Coronary Heart Disease
in Women. American Heart Association 71st Scientific Session. Circulation 1998 Oct
27;98(17 suppl):I-46.
Whitney EJ, Downs JR, Clearfield MB, Weis S, Stein EA, Shapiro DR, Beere PA, Gotto
AM. Air Force/Texas Coronary Atherosclerosis Prevention Study: Extending the Benefit
of Primary Prevention to Healthy Elderly Men and Women. American Heart Association
71st Scientific Session. Circulation 1998 Oct 27;98(17 suppl):I-46.
Downs JR, Clearfield MB, Weis SE, Kruyer WB, Whitney EA, Stein EA, Shapiro DR, Beere
PA, Gotto AM. Final results of the AFCAPS/TexCAPS coronary atherosclerosis prevention
study. American College of Cardiology Annual Scientific Session. Atlanta, GA, J American
Coll Cardio 31:280A, 1998.
Jones P. On Behalf of the Curves Investigators. Comparison of the dose efficacy of
atorvastatin with pravastatin, simvastatin, fluvastatin, and lovastatin. XIX Congress
of the European Society of Cardiology. 8/97.
Whitney EA, Clearfield MB, Downs JR, Shapiro DR, Stein EA, Beere PA, Gotto AM. Air
Force/Texas Coronary Atherosclerotic Prevention Study: Design and Baseline Characteristics.
American College of Cardiology. J American Coll Cardio 29: (2a):349A, 1997.
Downs JR, Beere PA, Whitney E, Clearfield MB, Weis S, Rochen J, Stein EA, Shapiro
DR, Langendorfer A, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention
(AFCAPS/TexCaps): Benefits and Rationale. Society of Air Force Physicians. 3/97.
Ward JM, Clearfield MB, McConathy WJ, Spellman CW. Pseudo-myelomas: elevated total
serum proteins associated with hypertriglyceridemia. American College of Osteopathic
Internists. 11/96.
McConathy WJ, Bousted S, Kudchodkar BJ, Nair M, Brett P, Clearfield MB, Lacko AG.
Interaction of LCAT and apolipoprotein D. International Symposium on the Role of HDL
in Disease Prevention. 11/96.
Pertusi RM, McConathy WJ, Chen MD, Lane DM, Weis SE, Clearfield MB, Lacko AG. High
frequency autoantibodies to phosphatyl serine in hyperlipidemia. 38th Annual AOA Research
Conference, 1994.
McConathy WJ, Chen Z, Pertusi RM, Lane DM, Weis SE, Clearfield MB, Lacko AG. High
frequency of autoantibodies to phosphatides. Seminar in Hypertension, UNTHSC Research
Appreciation Day, 3/94.
Clearfield MB, Weis SE, Fehl LM, Vasenius KA, Whitney E, Rochen J, Armstrong P, Fellows
M, Downs JR. TexCaps: the First Year's Experience. AOA Research Conference. Boston,
10/93.
Knebl J, DeFazio P, Clearfield MB, Little L, McConathy WJ, McPherson R, Lacko AG.
Plasma lipids and cholesterol esterification in Alzheimer's disease. Proc 62nd EAS
Congress. Jerusalem, Israel, 1993.
McConathy WJ, Chen Z, Weis SE, Clearfield MB, Lacko AG. Increased incidence of autoantibodies
to phospholipids in hyperlipoprotenemia. 66th Annual Meeting, American Heart Association.
p. 108, 1993.
Lacko AG, McPherson R, Weis SE, Clearfield MB, Kudchodkar BJ. Plasma lecithin: cholesterol
acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) as determinants
of changes in high density lipoprotein cholesterol (HDL-C) levels. Proc 2nd International
Symposium on High Density Lipoproteins. San Antonio, 2/92.
Kudchodkar BJ, Weis SE, Clearfield MB, Lacko AG. Factors influencing high density
lipoprotein cholesterol (HDL-C) levels. Proc 2nd International Symposium on High Density
Lipoproteins. San Antonio, 2/92.
Clearfield MB, Weis S, Kudchodkar BJ, Lacko AG. Factors influencing the increase in
high density lipoprotein cholesterol (HDL-C) by Gemfibrozil. ACOI Research Conference.
Boston, Mass, 10/91.
Weis S, Clearfield MB, Kudchodkar BJ, Lacko AG. Therapeutic efficacy of Gemfibrozil
for raising HDL cholesterol based on post-treatment triglyceride levels. AOA Research
Conference, 10/91. JAOA 91: 1032, 10/91.
Clearfield MB, Kudchodkar BJ, Weis SE, Lacko AG. The effects of Gemfibrozil on the
parameters of reverse cholesterol transport. Proc Nat Conf on Cholesterol and High
Blood Pressure Control. Washington, D.C., 5/91.
Clearfield MB, Kudchodkar BJ, Weis S, Lacko AG. The Effects of Gemfibrozil on the
Parameters of Reverse Cholesterol Transport. National Conference on Cholesterol and
High Blood Pressure Control. Washington, D.C., 4/91.
Clearfield MB, Fedorko S, McKinney ME. Osteopathic Medical Education: A Supportive
Environment for Preventive Cardiology Curriculum, 2nd International Conference on
Preventive Cardiology, 6/89
McKinney ME, Hofschire PJ, McIlvain HE, Fedorko S, Clearfield MB. Cardiovascular Reactivity
to Mental Stress: Does it Predict the Development of Cardiovascular Disease? 2nd International
Conference on Preventive Cardiology, Washington, D.C., 6/89.
Fedorko S, Clearfield MB, Physician Response to Hypercholesterolemia After Clinical
Redefinition and Educational Program. Southwestern Psychological Association, Houston,
Texas, 4/89.
Clearfield MB, Amerena J, Bassand JP, Hernandez-Garcia HR, Miller SS, Sosef FM, Palmer
MK, Bryzinski BS. Comparison of the efficacy and safety of rosuvastatin 10 mg and
atorvastatin 20 mg in high risk patients with hypercholesterolemia-Prospective study
to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)
Trials 2006;7:35 doi:1186/1745-6215-7-35
Clearfield M. Statins and the Primary Prevention of Cardiovascular Disease. Current
Atherosclerosis Reports. 2006;8:390-396
Alexander J, Clearfield M. Cardiovascular disease after menopause: a growing epidemic.
Minerva Ginecologica 2006;58:35-40.
Clearfield M. Clinical Trials Report
Current Atherosclerosis Reports 2006;8:7-12.
Clearfield M, Downs JR, Lee M, Langendorfer A, McConathy W, Gotto AM. Implications
from the Air Force/Texas Atherosclerosis Prevention Study for the Adult Treatment
Panel III Guidelines American Journal of Cardiology 2005;96:1674-1680
Yurvati AO, Carnes M, Clearfield M, Stoll S, McConathy WJ. Hemodynamic effects of
Osteopathic Manipulative Treatment immediately after coronary bypass surgery. Journal
of the American Osteopathic Association 2005;105:475-481
Clearfield M. C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease.
Journal of the American Osteopathic Association 2005;105:409-416.
Cholesterol Treatment Trialists (CTT) Efficacy and safety of cholesterol lowering
treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized
trial of statins. Lancet 2005;366:1267-1278.
Clearfield M. Clinical Trials Report
Current Atherosclerosis Reports 2005;7(1):7-10.
Clearfield MB. The Future looks promising for the Treatment of Patients with Coronary
Heart Disease. Journal of the American Osteopathic Association 2004;9:51-52
Clearfield M. Coronary Heart Disease Risk Reduction in Postmenopausal Women: The Role
of Statin Therapy and Hormone Replacement Therapy
Preventive Cardiology 2004;7:131-136
Girman CJ, Rhodes T, Mercuri M, Pyorala K, Pederson TR, Beere PA, Gotto AM, Clearfield
M. The Metabolic Syndrome and Risk of Major Coronary Events in the Scandinavian Simvastatin
Survival Study and the Air Force/Texas Coronary Atherosclerosis Prevention Study.
American Journal of Cardiology 2004;93:136-141.
Clearfield M. Future Directions in Dyslipidemia Management. John’s Hopkins University
Advanced Studies in Medicine. 2004;4(1B):S53-S60.
Clearfield M. Evolution of cholesterol management therapies: Exploiting potential
for further improvement. American Journal of Therapeutics 2003;Jul-Aug;10(4):275-281.
Clearfield MB. A novel therapeutic approach to dyslipidemia.
Journal American Osteopathic Association 2003;103(1):S16-S20.
Clearfield MB. The National Cholesterol Education Program Adult Treatment Panel III
Guidelines. Journal American Osteopathic Association 2003;103(1):S1-4.
Clearfield MB. Under-identification and under-treatment of dyslipidemia. Journal American
Osteopathic Association 2003;103(1):S5-8.
Clearfield MB, Weis SE, Willis JM, Vasenius KA, McConathy WJ. Lablility of serum low-density
lipoprotein cholesterol during screening of Air Force/Texas Coronary Atherosclerosis
Prevention Study (ACAPS/TexCAPS) cohort. Journal American Osteopathic Association
2002;102(7):377-384.
Ridker PM, Shih J, Cook TJ, Clearfield MB, Downs JR, Pradhan AD, Weis SE, Gotto AM.
Plasma Homocysteine Concentration, Statin Therapy, and the Risk of First Acute Coronary
Events. Circulation 2002;105:1776-1179.
Clearfield M Adult Treatment Panel III: Do we need another set of Cholesterol Guidelines.
Journal American Osteopathic Association 2002;102(5):S6-11.
Clearfield M. Statins: Balancing benefits, efficacy and safety.
Expert Opinion on Pharmacology. 2002;3(5):469-477.
Clearfield M, Downs JR, Weis S, Whitney EJ, Kruyer W, Shapiro D, Stein E, Langendorfer
A. Beere PA, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention Study:
Efficacy and Tolerability of Long-Term Treatment with Lovastatin in Women.
Journal of Women’s Health & Gender Based Medicine. 2001;10(10):1-11.
.Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles SJ, Gotto AM. Measurement
of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention
of Acute Coronary Events. New England Journal of Medicine. 2001;344(26):1959-1965.
Clearfield M. New Guidelines for the new millennium.
Journal American Osteopathic Association 2001;101(6):355,363.
Downs JR, Clearfield M, Tyroler A, Whitney EJ, Kruyer W, Langendorfer A, Zagrebelsky,
Shapiro D, Beere PA, Gotto Am. Air Force/Texas Coroanry Atherosclerosis Prevention
Study
(AFCAPS/TexCAPS): Additional Perspectives on Tolerability of Long-Term Treatment with
Lovastatin. American Journal of Cardiology 2001:87:1074-1079.
Gotto AM, Whitney E, Stein E, Shapiro DR, Clearfield M, Weis S, Jou J, Langendorfer
A, Beere P, Watson D, Downs JR, de Cani J. Relation Between Baseline and On-Treatment
Lipid parameters and First Acute Major Coronary Event in the Air Force/Texas Coronary
Atherosclerosis Prevention Study. Circulation. 2000;101:477-484.
Osborn GG, Meoli FG, Buser BR, Clearfield MB, Bruno JP, Sumner-Truax L. The Comprehensive
Osteopathic Medical Licensing Examination, COMLEX-USA:A new paradigm in testing and
evaluation. Journal American Osteopathic Association. 2000;100:105-111.
Clearfield M, Whitney EJ, Weis S, Downs JR, Shapiro DR, Stein EA, Watson DJ, Langendorfer
A, Beere PA, Stamler J, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention
Study (AFCAPS/TexCAPS): Baseline characteristics and comparison with USA population.
Journal of Cardiovascular Risk 2000;7:125-133.
Shores JH, Clearfield M, Alexander J. An Index of Students Satisfaction with Instruction.
Academic Medicine. 2000;75(10):S106-108.
Gotto Am, Boccuzzi SJ, Cook JR, Alexander CM, Roehm JB, Meyer GS, Clearfield MB, Weis
S, Whitney E. Effect of Lovastatin on Cardiovascular Resource Utilization and Costs
in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
American Journal of Cardiology 2000;86:1176-1181.
Mathe AJ, Clearfield MB. Long-term therapy of coronary artery disease: a vascular
biology perspective. Journal American Osteopathic Association 2000;100(11):S13-16.
Jones P, Kafoneh S, Laurera I, Hunninghake D, Curves Investigators. Comparative dose
efficacy study of Atorvastatin versus Simvastatin, Pravastatin, Lovastatin and Fluvastatin
in patients with hypercholesterolemia (Curves Study).
American Journal of Cardiology. 1998;81(5):582-587.
Lacko AG, Kudchodkar BJ, Loney WW, Clearfield MB, Weis S. Decrease in high density
lipoprotein cholesterol (HDL-C) levels following Gemfibrozil therapy.
Clinical Chemistry Laboratory Medicine 1998;36(6):389-92.
Downs JR, Clearfield MB, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A,
Stein EA, Kruyer MD, Gotto AM. Primary prevention of acute coronary events with Lovastatin
in men and women with average cholesterol levels results of AFCAPS/TexCAPS.
Journal American Medical Association. 1998;279:1615-1622.
Loney WW, Kudchodkar BJ, Weis SE, Clearfield MB, Shores J, Lacko AG. Evaluation of
gemfibrozil therapy: predictive response from lipoprotein subfraction analysis. American
Journal of Therapeutics.1997; 4:301-9.
Shen L, Cavaleri T, Clearfield M, Smoley J. Comparing medical knowledge of osteopathic
medical trainees in DO and MD programs: a random effect meta-analysis.
Journal of the American Osteopathic Association. 1997;97(6):359-362.
Downs JR, Beere PA, Whitney E, Clearfield M, Weis S, Rochen J, Stein EA, Shapiro D,
Langendörfer A, Gotto AM. Design and rationale of the Air Force/Texas coronary atherosclerosis
prevention study (AFCAPS/TEXCAPS).
American Journal of Cardiology. 1997;80:287-93..
Cholesterol Treatment Trialists (CTT) Collaboration. Protocol for a prospective collaborative
overview of all current and planned randomized trials of cholesterol treatment regimens.
Amercian Journal Cardiology. 1995;75:1130-1134.
Knebl J, DeFazio P, Clearfield MB, Little L, McConathy WJ, McPherson R, Lacko AG.
Plasma lipids and cholesterol esterification in Alzheimer's disease. Mechanisms of
Aging and Dev. 1994;73:69-77.
Clearfield MB, Lee N, Armstrong L, DeFazio P, Kudchodkar BJ, Lacko AG. The effect
of Captopril on the oxidation of low density lipoproteins (LDL) in vitro. Pharmacology
and Toxicology. 1994;75:218-221.
Clearfield MB, Wood HS, Vasenius KA. Risk factors other than hypertension and dyslipidemia
to be considered in preventive cardiology.
Journal of Osteopathic Medicine. 1993;14-31.
Clearfield MB. Current management approaches to hyperlipidemia.
Journal of the American Osteopathic Association. 1993(11suppl):1207-1211.
Clearfield MB. Therapeutic implications for dyslipidemia.
Journal of Osteopathic Medicine. 1992;(August):46-50.
Weis S, Clearfield MB, Kudchodkar B, Lacko A. The efficacy of Gemfibrozil therapy
for raising high density lipoprotein levels in hypertriglyceridemic patients. Artery
1992;19(6):353-367.
Lacko AG, Clearfield MB, Weis SE. The role of high density lipoproteins in determining
coronary risk. Tarrant County Physician. March, 1992.
Kudchodkar BJ, Weis SE, Clearfield MB, Lacko AG. Factors influencing plasma high density
cholesterol (HDL-C) levels upon treatment (Rx) with gemfibrozil. Arteriosclerosis
1991;(suppl).November.
Clearfield MB. The role of dyslipidemia in preventive cardiology.
Osteopathic Medical News, 1991;8(7):August.
Clearfield MB. The role of hypertension in preventive cardiology. Part 2.
Osteopathic Medical News, 1990;7(8):August.
Clearfield MB. The role of hypertension in preventive cardiology. Part 1.
Osteopathic Medical News, 1990;7(7):July.
Clearfield MB, Fedorko S, McKinney ME. Physician awareness of elevated cholesterol.
Journal of the American Osteopathic Association, 1990; 90:February.
Clearfield MB. Meperidine hydrochloride induced hypereosinophilia,
Journal of the American Osteopathic Association, 1987;87, September.
Clearfield MB, Trinkle PL. Hypokalemic subclinical neuromyopathy,
Journal of the American Osteopathic Association, 1986;86, December.
Trinkle PL, Clearfield MB. Primary hyperaldosteronism,
Journal of the American Osteopathic Association, 1983;83, November.
Duberstein DL, Efrusy ME, Clearfield MB, Lombardo PR. Primary sclerosing cholangitis
and cholangiocarcinoma: report of two cases,
Journal of the American Osteopathic Association, Vol. 1978;77:March.
Publications – Abstracts, Editorials, Book Chapters
Chapters/Reviews/Books
Weis S, Clearfield M, Downs J, Gotto A. The Air Force/Texas Coronary Atherosclerosis
Prevention Study: Primary Prevention of Acute Major Coronary Events in Women and Men
with Average Cholesterol. Cholesterol-Lowering Therapy-Evaluation of Clinical Trial
Evidence. Edited by Scott Grundy. Marcel Dekker Inc. 151-172, 2000.
Book Review: Clearfield MB. Review of General Internal Medicine: A Self-Assessment
Manual, Journal of the American Osteopathic Association, 1983.
Abstracts
Cui Y, Clearfield M. Non-High Density Lipoprotein Cholesterol is better than LDL-C
in Explaining the Reduction in First Acute Major Coronary Events with Statin Therapy:
A Secondary Analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study
ACC Epidemiology and Prevention 2007 Abstract Number 560
Clearfield M, Kallend D, Palmer M, Sosef F for the PULSAR study investigators. Efficacy
and Safety of Rosuvastatin 10 mg versus Atorvastatin 20 mg: Results of the PULSAR
study. Atherosclerosis 2005;6:104(W16-P-014).
Yurvati A, Carnes M, Clearfield M, Stoll S, McConathy W. Hemodynamic Effects of Osteopathic
Manipulative Treatment Immediately Following Coronary Artery Bypass Surgery. JAOA
2003;103(8):381 P11
Clearfield M, Gotto AM, Downs JR, Nag SS, Jiandong L, Alexander CM, Cook TJ, Beere
PA, Langendorfer A. Impact of Insulin Resistance on Acute Major Coronary Events in
the Air Force/Texas Coronary Atherosclerosis Prevention Study.
Diabetes;2002:Vol 51, suppl 2:pg 1A-738 # 627P.
Clearfield M. Overview of the Safety of Statin Treatment: An Update on Rosuvastatin.
American Society of Hospital Pharmacists. Atlanta Ga. 12/02
Gotto AM, Downs JR, Clearfield M, Weis S, Kruyer W, Whitney E, Stein EA. Follow-up
of the Air Force/Texas Coronary Atherosclerosis Prevention Study Cohort:Persistent
Benefit with Lovastatin Treatment. American Heart Association 74th Scientific Session,
Anaheim Cal 11/01
Ridker PM, Rifai N, Miles JS, Downs JR, Clearfield M, Gotto Am, Cook TJ, Weis S, Langendorfer
A, Beere PA. Relation Between Baseline Homocysteine Levels and Risk of Acute Major
Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study.
American Heart Association 74th Scientific Session, Anaheim Cal 11/01
Clearfield MB, Weis SE, Weiss M, McConathy WM. Hyporesponse to Lovastatin in the Texas
Coronary Atherosclerosis Prevention Study (TexCAPS) Cohort.
UNTHSC Research Appreciation Day 3/01
Shores JH, Clearfield M, Alexander J. An Index of Students Satisfaction with Instruction.
American Association of Medical Colleges, Research in Medical Education Conference.
Chicago Ill. 11/00.
Ridker PM, Rifai, Miles JS, Downs JR, Clearfield M, Gotto AM, Cookd TJ, Langendorfer
A, Beere PA. Lovastatin 20-40 mg/day Lowers High Sensitivity C-Reactive Protein Levels
in AFCAPS/TexCAPS.
American Heart Association 73rd Scientific Session, New Orleans, La. 11/00.
Ridker PM, Rifai N, Downs JR, Clearfield M, Gotto AM, Cook TJ, Langendorfer A. Beere
PA. Relation between baseline C-reactive protein levels and risk of acute major coronary
events in the Air Force/Texas Coronary Atherosclerosis Prevention Study. XXII Congress
of the European Society of Cardiology. Netherlands. European Heart Journal. 21:496,
#2728, 8/00.
Gotto AM. Beere PA, Allen SE, Cook JR, Downs JR, Clearfield M, Weis S Langenorfer
A. Air Force/Texas Atherosclerosis Prevention Study (AFCAPS/TexCAPS)- Benefits of
Lovastatin Treatment in Risk Subgroups Defined by Framingham Risk Equations. American
College of Cardiology 49th Scientific Session. Anaheim California, J American Coll
Cardio 35:313A, 2000.
Kruyer WB, Zagrebelsky V, Whitney EJ, Qinfen Y, Langerdorfer A Beere PA, Shapiiro
Farmer J, Downs JR, Clearfield M, Weis, Gotto AM. Air Force/Texas Atherosclerosis
Prevention Study (AFCAPS/TexCAPS) –The Effect of Treatment with Lovastatin on the
Utilization of Invasive Cardiac Procedures and the Extent of Angiographic Disease.
American College of Cardiology 49th Scientific Session. Anaheim California, J Americ
Coll Cardio 35:325A, 2000.
Gotto AM, Stein EA, Downs JR, Clearfield MB, Weis S, Whitney EJ, Beere PA, Shapiro
DR. Air Force/Texas Coronary Athreosclerosis Prevention Study (AFCAPS/TexCAPS):Relation
of Risk to Baseline Non-HDL Cholesterol. American Heart Association 72nd Scientific
Session. Atlanta, Ga. Circulation Supp I,100(18), I-197, #1017, 1999.
Gotto AM, Whiteny EJ, Stein EA, Shapiro DR, Clearfield MB, Weis SA, Beere PA, Watson
DJ, Downs JR, de Cani JS. Air Force/Texas Coronary Atherosclerosis Prevention Study:
Relative Benefitof Primary Prevention in Subgroups with Different Absolute Risk According
to US NCEP ATP II and Joint European Guidelines. XXI Congress of the European Society
of Cardiology. Barcelona, Spain. European Heart J, 20:473 (Supp #2495) Aug-Sept 1999.
Kruyer WB, Zagrebelsky V, Farmer J, Yu Q, Downs JR, Clearfield MB, Weis S, Whiteny
E, Shapiro DR, Beere PA, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention
Study: Invasive Procedures and Extent of Disease. XXI Congress of the European Society
of Cardiology. Barcelona, Spain. European Heart J, 20;238(Supp #1304) Aug-Sept 1999.
Stein E, Weis S, Downs JR, Clearfield M, Whitney E, Beere P, Gotto AM. Air Force/Texas
Coronary Atherosclerosis Prevention Study:Risk reduction by LDL-C and HDL-C tertiles.
European Atherosclerosis Society. 5/99.
Downs JR, Beere PA, Clearfield MB, Weis S, Whitney EJ, Shapiro DR, Kruyer WB, Watson
DJ, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention Study: Lipid Modification
and Risk Associated with Non-Lipid Risk Factors. American College of Cardiology. New
Orleans, J Amer Coll Cardio, 33:244A, 1999.
Gotto AM, Whitney EJ, Stein EA, Shapiro DR, Clearfield MB, Weis S, Watson DJ, Cook
JR, Beere PA, Downs JR. Predicting Risk of First Acute Major Coronary Events (AMCEs)
in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
American College of Cardiology. New Orleans, J Amer Coll Cardio, 33:263A, 1999.
Clearfield MB, Stein EA, Downs JR, Weis S, Whitney EJ, Shapiro DR, Beere PA, Gotto
AM. Air Force/Texas Coronary Atherosclerosis Prevention Study: Risk Reduction by NCEP
LDL-C Cutpoints. American Heart Association 71st Scientific Session. Circulation 1998
Oct 27;98(17 suppl):I-46.
Downs JR, Clearfield MB, Weis S, Whitney EJ, Shapiro DR, Beere PA, Gotto AM. Air Force/Texas
Coronary Atherosclerosis Prevention Study: Primary Prevention of Coronary Heart Disease
in Women. American Heart Association 71st Scientific Session. Circulation 1998 Oct
27;98(17 suppl):I-46.
Whitney EJ, Downs JR, Clearfield MB, Weis S, Stein EA, Shapiro DR, Beere PA, Gotto
AM. Air Force/Texas Coronary Atherosclerosis Prevention Study: Extending the Benefit
of Primary Prevention to Healthy Elderly Men and Women. American Heart Association
71st Scientific Session. Circulation 1998 Oct 27;98(17 suppl):I-46.
Downs JR, Clearfield MB, Weis SE, Kruyer WB, Whitney EA, Stein EA, Shapiro DR, Beere
PA, Gotto AM. Final results of the AFCAPS/TexCAPS coronary atherosclerosis prevention
study. American College of Cardiology Annual Scientific Session. Atlanta, GA, J American
Coll Cardio 31:280A, 1998.
Jones P. On Behalf of the Curves Investigators. Comparison of the dose efficacy of
atorvastatin with pravastatin, simvastatin, fluvastatin, and lovastatin. XIX Congress
of the European Society of Cardiology. 8/97.
Whitney EA, Clearfield MB, Downs JR, Shapiro DR, Stein EA, Beere PA, Gotto AM. Air
Force/Texas Coronary Atherosclerotic Prevention Study: Design and Baseline Characteristics.
American College of Cardiology. J American Coll Cardio 29: (2a):349A, 1997.
Downs JR, Beere PA, Whitney E, Clearfield MB, Weis S, Rochen J, Stein EA, Shapiro
DR, Langendorfer A, Gotto AM. Air Force/Texas Coronary Atherosclerosis Prevention
(AFCAPS/TexCaps): Benefits and Rationale. Society of Air Force Physicians. 3/97.
Ward JM, Clearfield MB, McConathy WJ, Spellman CW. Pseudo-myelomas: elevated total
serum proteins associated with hypertriglyceridemia. American College of Osteopathic
Internists. 11/96.
McConathy WJ, Bousted S, Kudchodkar BJ, Nair M, Brett P, Clearfield MB, Lacko AG.
Interaction of LCAT and apolipoprotein D. International Symposium on the Role of HDL
in Disease Prevention. 11/96.
Pertusi RM, McConathy WJ, Chen MD, Lane DM, Weis SE, Clearfield MB, Lacko AG. High
frequency autoantibodies to phosphatyl serine in hyperlipidemia. 38th Annual AOA Research
Conference, 1994.
McConathy WJ, Chen Z, Pertusi RM, Lane DM, Weis SE, Clearfield MB, Lacko AG. High
frequency of autoantibodies to phosphatides. Seminar in Hypertension, UNTHSC Research
Appreciation Day, 3/94.
Clearfield MB, Weis SE, Fehl LM, Vasenius KA, Whitney E, Rochen J, Armstrong P, Fellows
M, Downs JR. TexCaps: the First Year's Experience. AOA Research Conference. Boston,
10/93.
Knebl J, DeFazio P, Clearfield MB, Little L, McConathy WJ, McPherson R, Lacko AG.
Plasma lipids and cholesterol esterification in Alzheimer's disease. Proc 62nd EAS
Congress. Jerusalem, Israel, 1993.
McConathy WJ, Chen Z, Weis SE, Clearfield MB, Lacko AG. Increased incidence of autoantibodies
to phospholipids in hyperlipoprotenemia. 66th Annual Meeting, American Heart Association.
p. 108, 1993.
Lacko AG, McPherson R, Weis SE, Clearfield MB, Kudchodkar BJ. Plasma lecithin: cholesterol
acyltransferase (LCAT) and cholesteryl ester transfer protein (CETP) as determinants
of changes in high density lipoprotein cholesterol (HDL-C) levels. Proc 2nd International
Symposium on High Density Lipoproteins. San Antonio, 2/92.
Kudchodkar BJ, Weis SE, Clearfield MB, Lacko AG. Factors influencing high density
lipoprotein cholesterol (HDL-C) levels. Proc 2nd International Symposium on High Density
Lipoproteins. San Antonio, 2/92.
Clearfield MB, Weis S, Kudchodkar BJ, Lacko AG. Factors influencing the increase in
high density lipoprotein cholesterol (HDL-C) by Gemfibrozil. ACOI Research Conference.
Boston, Mass, 10/91.
Weis S, Clearfield MB, Kudchodkar BJ, Lacko AG. Therapeutic efficacy of Gemfibrozil
for raising HDL cholesterol based on post-treatment triglyceride levels. AOA Research
Conference, 10/91. JAOA 91: 1032, 10/91.
Clearfield MB, Kudchodkar BJ, Weis SE, Lacko AG. The effects of Gemfibrozil on the
parameters of reverse cholesterol transport. Proc Nat Conf on Cholesterol and High
Blood Pressure Control. Washington, D.C., 5/91.
Clearfield MB, Kudchodkar BJ, Weis S, Lacko AG. The Effects of Gemfibrozil on the
Parameters of Reverse Cholesterol Transport. National Conference on Cholesterol and
High Blood Pressure Control. Washington, D.C., 4/91.
Clearfield MB, Fedorko S, McKinney ME. Osteopathic Medical Education: A Supportive
Environment for Preventive Cardiology Curriculum, 2nd International Conference on
Preventive Cardiology, 6/89
McKinney ME, Hofschire PJ, McIlvain HE, Fedorko S, Clearfield MB. Cardiovascular Reactivity
to Mental Stress: Does it Predict the Development of Cardiovascular Disease? 2nd International
Conference on Preventive Cardiology, Washington, D.C., 6/89.
Fedorko S, Clearfield MB, Physician Response to Hypercholesterolemia After Clinical
Redefinition and Educational Program. Southwestern Psychological Association, Houston,
Texas, 4/89.
Clearfield MB. Physician Awareness to Elevated Cholesterol, 1st National Cholesterol
Meeting, Washington, D.C., 11/88
2010 Fellow, American College of Physicians
2010 Special Recognition Award, Osteopathic Physicians and Surgeons ofCalifornia
2009 Fellow, National Lipid Association
2009 National Academy of Osteopathic Medical Educators (NAOME inaugural class)
2006 Texas College of Osteopathic Medicine Yearbook Dedication
2005 Gutensohn-Denslow Award
2005 Top Doctors in Tarrant County in Internal Medicine- Fort Worth Magazine
2004 Darryl A. Beehler, DO Research Mentor of the Year Award
2003 American Osteopathic Foundation’s Astra-Zeneca Healthy Heart Award
2003 Top Doctors in Tarrant County in Internal Medicine-Fort Worth Magazine
2002- Osteopathic Heritage Foundation Distinguished Chair in Clinical Research
1999 President’s Citation
Chicago College of Osteopathic Medicine
1997 Internist of the Year
American College of Osteopathic Internists
1995 Outstanding Achievement Award
Chicago College of Osteopathic Medicine Alumni Association
1988 Fellow, American College of Osteopathic Internists
|
Employer |
Title |
From - To |
|
Touro University College of Osteopathic Medicine |
Dean |
8/06-present |
|
University of North Texas Health Science Center Clinical |
Professor, Department of Internal |
2006-2008 |
|
National Board of Osteopathic Medical Examiners Member |
Research Committee |
2005-present |
|
Nor Tex Scientific |
Review Committee |
2005-2006 |
|
Texas College of Osteopathic Medicine, University of North Texas Health Science Center |
Dean for Clinical Research |
2002-2006 |
|
Osteopathic Research Center |
Executive Committee |
2002-2006 |
|
American Osteopathic Association |
Council on Research Member |
2002-2005 |
|
American Osteopathic Association |
Council on Research Chair |
2002-2004 |
|
American Osteopathic Association (AOA) |
Representative to the National Cholesterol Education Program |
1995-present |
|
University of North Texas Health Science Center |
Professor of Medicine, Department of Medicine |
1991-2006 |
|
University of North Texas Health Science Center |
Co-Director, Heart Disease Prevention |
1990 – 2006 |
|
University of North Texas Health Science Center |
Chairman, Department of Medicine |
1985 – 2002 |
|
Texas College of Osteopathic Medicine |
Acting Chairman, Department of Medicine |
1982 – 1985 |
|
Texas College of Osteopathic Medicine |
Vice Chairman, Department of Medicine |
1980 – 1982 |
|
Texas College of Osteopathic Medicine |
Associate Professor of Medicine, Department of Medicine |
1983 – 1991 |
|
Baylor College of Medicine |
Adjunct Assistant Professor of Medicine |
1991 – 2006 |
|
Texas College of Osteopathic Medicine |
Assistant Professor of Medicine, Department of Medicine |
1979 – 1983 |
Our Judaic Values Touro College Touro Western Division Touro Nevada Campus Safety Privacy Policy Contact Us Master Calendar Title IX
Copyright 2005 - 2020, Touro University, All Rights Reserved.